Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

被引:36
|
作者
Kim, Jin You [1 ,2 ]
Kim, Jin Joo [1 ]
Hwangbo, Lee [1 ]
Lee, Ji Won [1 ]
Lee, Nam Kyung [1 ]
Nam, Kyung Jin [3 ]
Choo, Ki Seok [3 ]
Kang, Taewoo [4 ]
Park, Heeseung [4 ]
Son, Yohan [5 ]
Grimm, Robert [6 ]
机构
[1] Pusan Natl Univ Hosp, Med Res Inst, Dept Radiol, Busan, South Korea
[2] Pusan Natl Univ, Dept Radiol, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea
[3] Pusan Natl Univ, Dept Radiol, Yangsan Hosp, Yangsan, South Korea
[4] Pusan Natl Univ Hosp, Busan Canc Ctr, Busan, South Korea
[5] Siemens Healthineers Ltd, Seoul, South Korea
[6] Siemens Healthcare GmbH, Erlangen, Germany
关键词
Diffusion magnetic resonance imaging; Breast neoplasms; Oncotype DX; Recurrence; Biomarkers; ADJUVANT SYSTEMIC THERAPY; ONCOTYPE-DX; AMERICAN-SOCIETY; EARLY-STAGE; TUMOR HETEROGENEITY; GENE-EXPRESSION; COEFFICIENT; CHEMOTHERAPY; WOMEN; SURVIVAL;
D O I
10.1007/s00330-019-06383-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. Methods This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated. Results Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS >= 18; intermediate to high risk of recurrence) groups (0.600 x 10(-3) mm(2)/s vs. 0.746 x 10(-3) mm(2)/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 x 10(-3) mm(2)/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (<= 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors. Conclusions The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
引用
收藏
页码:66 / 76
页数:11
相关论文
共 50 条
  • [11] Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
    Ji, Jung Hwan
    Bae, Soong June
    Kim, Kyungsoo
    Chu, Chihhao
    Lee, Kyung-A
    Kim, Yoonjung
    Kim, Jee Hung
    Jeong, Joon
    Ahn, Sung Gwe
    NPJ BREAST CANCER, 2022, 8 (01)
  • [12] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
    Almstedt, K.
    Mendoza, S.
    Otto, M.
    Battista, M. J.
    Steetskamp, J.
    Heimes, A. S.
    Krajnak, S.
    Poplawski, A.
    Gerhold-Ay, A.
    Hasenburg, A.
    Denkert, C.
    Schmidt, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
  • [13] Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer
    Vera-Badillo, Francisco E.
    Chang, Martin C.
    Kuruzar, Gordana
    Ocana, Alberto
    Templeton, Arnoud J.
    Seruga, Bostjan
    Goldstein, Robyn
    Bedard, Philippe L.
    Tannock, Ian F.
    Amir, Eitan
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (10) : 839 - 843
  • [14] Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
    Albain, Kathy S.
    Gray, Robert J.
    Makower, Della F.
    Faghih, Amir
    Hayes, Daniel F.
    Geyer, Charles E., Jr.
    Dees, Elizabeth C.
    Goetz, Matthew P.
    Olson, John A., Jr.
    Lively, Tracy
    Badve, Sunil S.
    Saphner, Thomas J.
    Wagner, Lynne, I
    Whelan, Timothy J.
    Ellis, Matthew J.
    Wood, William C.
    Keane, Maccon M.
    Gomez, Henry L.
    Reddy, Pavan S.
    Goggins, Timothy F.
    Mayer, Ingrid A.
    Brufsky, Adam M.
    Toppmeyer, Deborah L.
    Kaklamani, Virginia G.
    Berenberg, Jeffrey L.
    Abrams, Jeffrey
    Sledge, George W., Jr.
    Sparano, Joseph A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (04): : 390 - 399
  • [15] 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
    Turashvili, Gulisa
    Chou, Joanne F.
    Brogi, Edi
    Morrow, Monica
    Dickler, Maura
    Norton, Larry
    Hudis, Clifford
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 69 - 76
  • [16] Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
    Yu, Ke-Da
    Jiang, Yi-Zhou
    Hao, Shuang
    Shao, Zhi-Ming
    BMC MEDICINE, 2015, 13
  • [17] Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer
    Baltres, Aline
    Al Masry, Zeina
    Zemouri, Ryad
    Valmary-Degano, Severine
    Arnould, Laurent
    Zerhouni, Noureddine
    Devalland, Christine
    BREAST CANCER, 2020, 27 (05) : 1007 - 1016
  • [18] What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
    Ando, Kenju
    Shimomura, Akihiko
    Yoshimura, Kenichi
    Kawamura, Yukino
    Shimizu, Chikako
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1946 - +
  • [19] Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Iwamoto, Takayuki
    Kelly, Catherine
    Mizoo, Taeko
    Nogami, Tomohiro
    Motoki, Takayuki
    Shien, Tadahiko
    Taira, Naruto
    Hayashi, Naoki
    Niikura, Naoki
    Fujiwara, Toshiyoshi
    Doihara, Hiroyoshi
    Matsuoka, Junji
    CLINICAL BREAST CANCER, 2016, 16 (02) : 95 - 100
  • [20] Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer
    Holowatyj, Andreana N.
    Cote, Michele L.
    Ruterbusch, Julie J.
    Ghanem, Kristina
    Schwartz, Ann G.
    Viguerm, Fawn D.
    Gorski, David H.
    Purrington, Kristen S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) : 652 - +